The DOI matches its OpenAlex record.
Eculizumab treatment in patients with COVID-19: preliminary results from real life ASL Napoli 2 Nord experience.
Open accessAbstract
OBJECTIVE: SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2)-related pneumonia, referred to as COVID-19 (Coronavirus Disease 19), is a public health emergency as it carries high morbidity, mortality, and has no approved specific pharmacological treatments. In this case series, we aimed to report preliminary data obtained with anti-complement C5 therapy with eculizumab in COVID-19 patients admitted to intensive care unit (ICU) of ASL Napoli 2 Nord. PATIENTS AND METHODS: This is a case series of patients with a confirmed diagnosis of SARS-CoV2 infection and severe pneumonia or ARDS who were treated with up to 4 infusions of eculizumab as an off-label agent. Patients were also treated with anticoagulant therapy with Enoxaparin 4000 IU/day via subcutaneous injection, antiviral therapy with Lopinavir 800 mg/day + Ritonavir 200 mg/day, hydroxychloroquine 400 mg/day, ceftriaxone 2 g/day IV, vitamine C 6 g/day for 4 days, and were on Non-Invasive Ventilation (NIV). RESULTS: We treated four COVID-19 patients admitted to the intensive care unit because of severe pneumonia or ARDS. All patients successfully recovered after treatment with eculizumab. Eculizumab induced a drop in inflammatory markers. Mean C Reactive Protein levels dropped from 14.6 mg/dl to 3.5 mg/dl and the mean duration of the disease was 12.8 days. CONCLUSIONS: Eculizumab has the potential to be a key player in treatment of severe cases of COVID-19. Our results support eculizumab use as an off-label treatment of COVID-19, pending confirmation from the ongoing SOLID-C19 trial.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Characteristics of SARS-CoV-2 and COVID-19
Hu, B., Guo, H., Zhou, P., & Shi, Z.-L. (2021) · Nature Reviews Microbiology · doi:10.1038/s41579-020-00459-7 · Cited by 5,291
Goshua, G., Pine, A. B., Meizlish, M. L., Chang, C.-H., Zhang, H., Bahel, P., Baluha, A., Bar, N., Bona, R. D., Burns, A. J., et al. (2020) · The Lancet Haematology · doi:10.1016/s2352-3026(20)30216-7 · Cited by 1,110
Endothelial dysfunction and immunothrombosis as key pathogenic mechanisms in COVID-19
Bonaventura, A., Vecchié, A., Dagna, L., Martinod, K., Dixon, D. L., Van Tassell, B. W., Dentali, F., Montecucco, F., Massberg, S., Levi, M., et al. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-021-00536-9 · Cited by 987
Association of COVID-19 inflammation with activation of the C5a–C5aR1 axis
Carvelli, J., Demaria, O., Vély, F., Batista, L., Chouaki Benmansour, N., Fares, J., Carpentier, S., Thibult, M.-L., Morel, A., Remark, R., et al. (2020) · Nature · doi:10.1038/s41586-020-2600-6 · Cited by 526
The vascular endothelium: the cornerstone of organ dysfunction in severe SARS-CoV-2 infection
Pons, S., Fodil, S., Azoulay, E., & Zafrani, L. (2020) · Critical Care · doi:10.1186/s13054-020-03062-7 · Cited by 517
Metadata
- Authors
- Diurno, F., Numis, F. G., Porta, G., Cirillo, F., Maddaluno, S., Ragozzino, A., Negri, P. D., Gennaro, C. D., Pagano, A., Allegorico, E., Bressy, L., Bosso, G., Ferrara, A., Serra, C. G., Montisci, A., D’amico, M., Morello, S. S. L., Costanzo, G. D., Tucci, A. G., Marchetti, P., Vincenzo, U. D., Sorrentino, I., Casciotta, A., Fusco, M., Buonerba, C., Berretta, M., Ceccarelli, M., Nunnari, G., Diessa, Y., Cicala, S., & Facchini, G.
- Venue
- PubMed
- Publisher
- National Institutes of Health
- Published
- 2020-04-01
- Volume
- 24
- Issue
- 7
- Pages
- 4040-4047
- OpenAlex
- W3018424597
- Cited by
- 326
- References
- 0
- FWCI
- 9.45
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Eculizumab treatment in patients with COVID-19: preliminary results from real life ASL Napoli 2 Nord experience. https://app.cochat.ai/papers/10.26355/eurrev_202004_20875
- The paper
- Diurno, F., Numis, F. G., Porta, G., Cirillo, F., Maddaluno, S., Ragozzino, A., Negri, P. D., Gennaro, C. D., Pagano, A., Allegorico, E., Bressy, L., Bosso, G., Ferrara, A., Serra, C. G., Montisci, A., D’amico, M., Morello, S. S. L., Costanzo, G. D., Tucci, A. G., . . . Facchini, G. (2020). Eculizumab treatment in patients with COVID-19: preliminary results from real life ASL Napoli 2 Nord experience. PubMed. https://doi.org/10.26355/eurrev_202004_20875
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.